EUVIMEDEUVIMED entdecken
Crossref

Structure-Based Design and Molecular Docking Analysis of Uridine-Based and Muraymycin C2 Inhibitors Targeting MraY Translocase in Clinical Isolates Pseudomonas aeruginosa

Hawraa Natiq Kabroot AL-Fatlawy

International Journal of Environmental and Biological Sciences · 31.10.2026 · 1 (4)

DOI: 10.63939/f4e8jf34 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Environmental and Biological Sciences, online erschienen am 31.10.2026. Verfasst von Hawraa Natiq Kabroot AL-Fatlawy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Multidrug resistance (MDR) Pseudomonas aeruginosa has become a major clinical problem because of its resistance to a variety of antibiotic classes and the limited number of effective therapy options.

Objectives

This study was to perform structure-based design, molecular docking and molecular characterization of Uridine-based and Liponucleoside derivatives of essential translocase in MDR P. aeruginosa (MraY).

Results

An antimicrobial resistance profile of (44) forty-four isolates of P. aeruginosa revealed high levels of resistance to, cefotaxime, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole (100%), and 60% of strains were resistant to the carbapenems. All the clinical isolates were positive results in PCR for the presence of MraY gene, it conserved a widespread distribution, and therapeutic importance. Cavity detection and virtual screening in five possible binding pockets resulted in Cavity1 (C1) having a volume of 1819 Å3 at the coordinates (-20, -1, 14) being the main catalytic active site. The natural reference inhibitor Muraymycin C2 showed a high binding interaction of -9.6 kcal/mol within the C1, with significant interactions with the residue ASP115, ASP116, SER120 and THR73. While, the candidate ligand, Uridine 5ˈ-monophosphate, showed a stable and consistent binding score of (-7.6 kcal /mol) in C1, with supporting hydrogen bonds with ALA56, ASP116 and THR71. ADMET and toxicological profiling indicated that Uridine 5ˈ-monophosphate possesses a favorable molecular weight (324.18 g/mol) and compliance with drug-like properties, while both evaluated ligands exhibited exceptionally clean safety profiles, showing no mutagenicity (AMES), hepatotoxicity, cardiotoxicity (hERG) or skin sensitization risks.

Conclusions

The findings highlight that while Muraymycin C2 serves as a high-affinity natural benchmark, the uridine-based scaffold provides a non-toxic and chemically tractable framework for future lead optimization against MDR P. aeruginosa.

Zitieren

APA

AL-Fatlawy, H. N. K. (2026). Structure-Based Design and Molecular Docking Analysis of Uridine-Based and Muraymycin C2 Inhibitors Targeting MraY Translocase in Clinical Isolates Pseudomonas aeruginosa. International Journal of Environmental and Biological Sciences, 1(4). https://doi.org/10.63939/f4e8jf34

Vancouver

AL-Fatlawy HNK. Structure-Based Design and Molecular Docking Analysis of Uridine-Based and Muraymycin C2 Inhibitors Targeting MraY Translocase in Clinical Isolates Pseudomonas aeruginosa. International Journal of Environmental and Biological Sciences. 2026;1(4). doi:10.63939/f4e8jf34

BibTeX
@article{ALFatlawy2026,
  author = {AL-Fatlawy, Hawraa Natiq Kabroot},
  title = {Structure-Based Design and Molecular Docking Analysis of Uridine-Based and Muraymycin C2 Inhibitors Targeting MraY Translocase in Clinical Isolates Pseudomonas aeruginosa},
  journal = {International Journal of Environmental and Biological Sciences},
  year = {2026},
  volume = {1},
  number = {4},
  doi = {10.63939/f4e8jf34}
}
Kostenlos starten →